Introduction {#Sec1}
============

The primary headaches covered in this review are tension-type headache (TTH), migraine and cluster headache (CH). All three entities occur in both men and women, yet display a sex-specific prevalence. These gender differences suggest that both male and female sex hormones could have an influence on the course of primary headaches.

TTH has a female preponderance, and is 1.5 times more frequent in women than in men \[[@CR1]\]. CH, on the other hand, appears to have a higher incidence in men, specifically during young adulthood and middle age. Later in life the prevalence of CH evens out between the sexes \[[@CR2]\]. Within the group of primary headaches the role of sex hormones has been studied most profoundly in migraine. Prepubertal children have a 3-10% prevalence of migraine without any gender difference \[[@CR3], [@CR4]\]. With onset of puberty and its associated hormonal changes, migraine becomes 2--3 times more common in women than in men, suggesting that migraine is influenced by the fluctuating hormonal status through menarche, menstruation, pregnancy, menopause, as well as the use of oral contraceptives and hormonal replacement therapy (HRT) \[[@CR1], [@CR3], [@CR5]--[@CR8]\].

In contrast, the course of migraine throughout the lifespan of men appears relatively stable, further pointing to the unique role of female sex hormones in the migraine phenotype \[[@CR1]\]. Here, we summarise relevant literature of the last 20 years covering the influence of female and male sex hormones on primary headaches.

Search strategy and selection criteria {#Sec2}
======================================

Two independent reviewers conducted a search on PubMed, using their own search string, composed of terms like LH, FSH, Progesteron\*, estrogen\*, DHEA\*, Prolactin, Testosterone, androgen\*AND Headach\* OR Migrain\* OR "Tension type" OR Cluster. This general search was performed on December 7th, 2017. In light of the large amount of published work on the topic and considering the evolution of the diagnostic criteria over time, the first search was conducted respecting a timeframe of 20 years, covering articles published after January 1st 1997. The initial screening was performed based on eligibility of title and abstract. Exclusion criteria included non-availability of abstract, animal studies, and articles in any language other than English. Original studies, published in full, constitute the core of this review. Other quoted references include systematic reviews, case reports, meta-analysis, Cochrane reviews, letters, lectures and comments. Any relevant publications cited in the eligible articles were also included. Differences between reviewers were resolved by careful discussion.

Results {#Sec3}
=======

Women {#Sec4}
-----

### Childhood and adolescence {#Sec5}

Almost 60% of girls and 50% of boys suffer from headache at some time during childhood and adolescence, with the prevalence increasing significantly during adolescence in girls, whereas it remains stable for boys \[[@CR9]\]. The incidence of migraine is similar in both sexes until the age of 9 (2.5% of girls and 2.4% of boys) and then diverges to the disadvantage of girls \[[@CR6]\]. Teenagers who suffer from headache are at greater risk of having headache in adulthood \[[@CR9]\].

It is known that during puberty, sexual steroid hormones affect neural circuits and cause permanent changes in important brain areas such as the hypothalamus and the insula \[[@CR4]\]. Onset of migraine frequently occurs around the time of menarche, as cyclic hormonal changes begin. Early menarche appears to be a risk factor for the development of migraine \[[@CR6], [@CR10]\]. Notably, the first menstrual cycles are often anovulatory and in general ovulation occurs one or two years later. In the USA, the average age of menarche is 12.8 years, but this may vary geographically. Migraine with aura has an incidence peak between ages 12 to 13, while migraine without aura typically presents a few years later. Thus, migraine without aura may be associated with the establishment of a regular ovulatory menstrual cycle \[[@CR7]\]. Headaches are reported in 53% of adolescent girls at the onset of menses. Pubertal development and age seem to modulate the effect of ovarian hormones on migraine. In fact, high urinary levels of pregnandiol glucuronide, a metabolite of progesterone, are associated with a higher migraine frequency in girls before menarche, but with a lower frequency after menarche \[[@CR11]\]. Hershey et al. identified specific genomic patterns in girls suffering from menstrual migraine, suggesting a genetic predisposition for the development of this condition during adolescence \[[@CR12]\].

TTH shows a similar, increasing trend in girls by the time of menarche. The incidence ratio between boys and girls changes from 1.3:1 during childhood to 1:1.2 after menarche \[[@CR13]\].

It is noteworthy to mention, that pathological changes in sexual hormones can cause a secondary headache. For instance, hyperprolactinemia manifests in up to 45% of childhood cases with headache as a first symptom \[[@CR14]--[@CR16]\].

### Adulthood {#Sec6}

#### Migraine {#FPar1}

Women have a 3.25-fold higher risk of suffering from migraine than men \[[@CR17]\]. A prevalence peak is reached in women between the ages of 35 and 45, with 25-30% of the general female population being affected, in comparison to only 8% of the general male population \[[@CR18]\]. Female migraine patients also report a significant higher burden of disease and greater use of analgesic compared to men \[[@CR6], [@CR13]\].

In terms of deciphering the pathophysiological mechanism of the preponderance of migraine in women, neuroimaging studies have revealed sex-specific activation patterns, with an increased activation of the insula and precuneus in women. These regions are involved in pain, sensation and affective processing \[[@CR19]\]. Sex hormones can cross the blood-brain barrier passively and are at least partially responsible for these sex differences \[[@CR18]\]. Most available literature focuses on the effects of estrogen, while the role of progesterone has been less thoroughly investigated.

The relationship between estrogen and migraine is complex, involving modulation by genomic and non-genomic effects \[[@CR20], [@CR21]\]. Obese women appear to have more than a twofold risk of episodic and chronic migraine, probably due to the pathological estrogen production in adipose tissue \[[@CR22], [@CR23]\]. Substantial evidence points to the serotonergic system as a key player in migraine pathogenesis \[[@CR7]\]. Estrogen modulates serotonergic neurotransmission, by increasing the expression of the tryptophan hydroxylase and decreasing the expression of the serotonin reuptake transporter \[[@CR7], [@CR24], [@CR25]\]. Estrogen also activates the endogenous opioidergic system, which has an analgesic effect on persistent, inflammatory pain \[[@CR26]\]. Furthermore, estrogen induces vascular changes by modulating vasodilation and suppressing vascular inflammatory responses \[[@CR6], [@CR27], [@CR28]\].

The levels of calcitonin gene-related peptide (CGRP), a neuropeptide with a key role in migraine pathophysiology, are higher in women of reproductive age than in men. Cyclic hormonal fluctuations influence CGRP release and consequently the trigeminovascular system \[[@CR29]\]. While studies have reported a positive relationship between CGRP and estrogen levels, newer studies suggest an inverse relationship between the two \[[@CR24]\].

Experimental studies suggest progesterone to play a protective role, by reducing nociception in the trigeminovascular system, inhibiting neurogenic edema, and histamine secretion from mast cells and decreasing prostaglandin production \[[@CR7], [@CR24], [@CR30], [@CR31]\].

Multiple studies have examined the association between polymorphisms in estrogen or progesterone receptor genes and migraine risk, with inconclusive findings \[[@CR32]--[@CR37]\]. In their meta-analysis, Schürks et al. and Li et al. concluded that exon 4 325C \> G and exon 8 594G \> A polymorphisms are risk factors for migraine, while the often examined PROGINS variant in the progesterone receptor gene did not seem to play a significant role in the Caucasian population \[[@CR38], [@CR39]\]. On the contrary, Joshi et al. found a protective role of the PROGINS polymorphism in an Indian population \[[@CR40]\].

Prolactin could also play a modulatory role in migraine. Parashar et al. found higher prolactin levels in migraineurs compared to controls \[[@CR41]\]. An association between high prolactin levels and migraine chronification has been proposed by Cavestro et al. \[[@CR42]\], where Peres et al. detected decreased nocturnal prolactin peaks in chronic migraine patients \[[@CR43]\].

There are a few reports suggesting that testosterone can play a role in migraine in women \[[@CR44], [@CR45]\]. In one case report, the 5α reductase inhibitor finasteride was administered to a young woman with migraine and led to an almost complete remission \[[@CR45]\]. The mechanism of action of testosterone on migraine pathophysiology is still unknown, but may involve modulation of cerebral blood flow, serotonergic tone, and susceptibility to cortical spreading depression \[[@CR44]\].

#### Menstrual migraine {#FPar2}

The probability of migraine to occur during the perimenstrual period is twice as high compared to any other moment of the menstrual cycle \[[@CR46]\]. Almost half of female migraine patients report an association between headache and their menstrual cycle \[[@CR17]\]. Depending on whether migraine occurs exclusively during the perimenstrual period or also at other times, the International Headache Society (IHS) distinguishes a pure menstrual migraine from a menstrually-related migraine (Table [1](#Tab1){ref-type="table"}). Migraine associated with menstruation is mostly of the type without aura \[[@CR21]\].Table 1IHS classification (ICHD-3) for pure menstrual and menstrually-related migrainePure menstrual migraineMenstrually-related migraineA. Attacks, in a menstruating woman, fulfilling criteria for migraine without auraA. Attacks, in a menstruating woman, fulfilling criteria for migraine without auraB. Attacks occur exclusively on day 1 ± 2 (i.e, days − 2 to + 3)^a^ of menstruation^b^ in at least two out of three menstrual cycles and at no other times of the cycleB. Attacks occur on day 1 ± 2 (i.e, days − 2 to + 3)^a^ of menstruation^b^ in at least two out of three menstrual cycles and additionally at other times of the cycle^a^The first day of menstruation is day 1 and the preceding day is day − 1; there is no day 0^b^For the purposes of this classification, menstruation is considered to be endometrial bleeding resulting from either the normal menstrual cycle or from the withdrawal of exogenous progestogens, as in the case of combined oral contraceptives and cyclical hormone replacement therapy

Pure menstrual migraine and menstrually-related migraine have an overall prevalence of respectively 1% and 7% in the general population \[[@CR47]\]. Data from specialized headache clinics suggest that perimenstrual attacks are more severe, long-lasting and difficult to treat with abortive anti-migraine medication \[[@CR48]\]. However, these results could not be confirmed in the general population \[[@CR49]\]. Menstrual migraine appears to limit work and social activities more frequently than common migraine and is often associated with a dysphoric mood \[[@CR17]\].

The "Estrogen withdrawal hypothesis", developed by Somerville and colleagues in 1972, postulates that attacks of menstrual migraine are triggered by the decrease in estrogen levels preceding menstruation \[[@CR21]\]. A drop in estrogen may cause an increased sensitivity to prostaglandins and a release of neuropeptides such as CGRP, substance P and neurokinins which could result in neurogenic inflammation \[[@CR17]\]. This physiological response provokes alterations in the microvasculature of the dura mater, changes in calcium and magnesium concentrations, and an imbalance in serotonin and dopamine concentrations \[[@CR17], [@CR21], [@CR50]\]. Estrogen withdrawal might lead to an increased oxidative stress in the cells \[[@CR51]\]. To confirm this hypothesis, intramuscular injections of estrogen were administered before menstruation and thereby postponing migraine attacks \[[@CR52], [@CR53]\]. On the contrary, progesterone injections only led to postpone menses, but not migraine \[[@CR52], [@CR54]\].

More recent studies confirm that an estrogen drop can trigger migraine, especially if this drop is preceded by a phase of high estrogen levels, as in the luteal phase of the menstrual cycle, and if the magnitude of the decrease is greater than 10 μg \[[@CR55], [@CR56]\]. Interestingly, women with migraine seem to have a faster drop in estrogen levels than non-migraineurs \[[@CR57]\].

Welch et al. tried to explain estrogen effects on menstrual migraine with a "mismatch theory". Under normal circumstances, genomic effects of estrogen can counterbalance non-genomic mediated membrane excitability. In low estrogen states, this inhibiting genomic effect does not suffice, and migraine attacks occur more frequently \[[@CR58], [@CR59]\].

In one retrospective study with 85 female patients with menstrual migraine, 35.3% reported migraine headache onset by the end of menstruation, which is days after the estrogen drop. The authors hypothesize that this type of migraine headache is not related to hormonal changes but most probably to transient anemia due to blood loss \[[@CR56]\].

Hormonal treatment of menstrual migraine, like perimenstrual application of estrogen gel or a transdermal estradiol patch, can lead to less frequent, shorter and less intensive attacks \[[@CR46], [@CR47], [@CR52], [@CR60]\]. Attacks may recur after discontinuation of hormonal treatment \[[@CR17]\]. Following the estrogen withdrawal hypothesis, eliminating estrogen cycling appears to be a useful strategy for long-term prophylaxis of menstrual migraine. Therefore, continuous combined contraceptive therapy regimes, containing both estrogen and progesterone, can be considered. However, there is currently no evidence that hormonal therapy is more effective than non-hormonal pharmacological treatment strategies. Hormonal therapy is particularly recommended if other indications like acne or hirsutism exist. Contraindications should be ruled out \[[@CR17], [@CR53]\]. Alternatively, progesterone-only contraceptives can be considered. A significant reduction in migraine intensity and frequency is reported \[[@CR17], [@CR61]--[@CR63]\]. As progesterone has no experimental effect on cortical spreading depression, progesterone-only contraception is hypothesized to be a safer choice for women with aura \[[@CR62], [@CR64]\], but no clinical evidence has confirmed this theory. The selective estrogen receptor modulator Tamoxifen might also be beneficial in women with menstrual migraine. However, its use is not generally recommended due to possible and in part serious side effects \[[@CR65]\]. Some studies suggest that phytoestrogens like soy isoflavone, dong quai or black cohosh could have a beneficial effect on migraine \[[@CR17]\]. Martin et al. examined the efficacy of the gonadotropin-releasing hormone antagonist goserelin as a prophylactic therapy. Goserelin alone did not affect migraine headache frequency. Some benefit was obtained when combined with 100 μg estradiol \[[@CR66]\]. Glaser et al. demonstrated that continuous testosterone therapy through a subcutaneous implant for 3 months led to headache improvement in 92% of migraine patients \[[@CR44]\].

#### Migraine with aura {#FPar3}

The female dominance is also seen in migraine with aura. In prevalence studies performed after 1988 it reaches a prevalence of 1.2-3.7% in men and 2.6-10.8% in women \[[@CR67]\]. In contrast to menstrual migraine, migraine with aura occurs more frequently with high estrogen levels \[[@CR68]\]. Estrogen seems to change cortical susceptibility and contributes to the development of cortical spreading depression. The amplitude of the spreading depression depends on the estrogen level \[[@CR69]\]. The threshold for cortical excitability and subsequent cortical spreading depression is lowered through several genomic and non-genomic mechanisms, including upregulation of NMDA receptors, downregulation of GABA neurons and modulation of axonal plasticity \[[@CR4], [@CR69], [@CR70]\].

#### Exogenous hormone-induced headache {#FPar4}

In the Western world, almost one third of women of reproductive age use oral contraception \[[@CR55]\]. The IHS identifies two headache entities related to the use of hormonal contraceptives: exogenous hormone-induced headache and estrogen-withdrawal headache (Table [2](#Tab2){ref-type="table"}).Table 2IHS classification (ICHD-3) for exogenous hormone-induced headache and estrogen-withdrawal headacheExogenous hormone-induced headacheEstrogen-withdrawal headacheA. Headache or migraine fulfilling criteria C and DA. Headache or migraine fulfilling criteria C and DB. Regular use of exogenous hormonesB. Daily use of exogenous estrogen for ≥3 weeks, which has been interruptedC. Headache or migraine develops or markedly worsens within 3 months of commencing exogenous hormonesC. Headache or migraine develops within 5 days after last use of estrogenD. Headache or migraine resolves or reverts to its previous pattern within 3 months after total discontinuation of exogenous hormonesD. Headache or migraine resolves within 3 days of its onset

Headache is one of the most common side effects of hormonal therapies \[[@CR71]\]. For instance Tamoxifen, mentioned above as a possible treatment for menstrual migraine, can also cause headache. The onset of hormone-induced headache is typically within the first months of use \[[@CR72]\]. Combined contraception remedies (oral pill, transdermal patch, vaginal ring) appear to be associated with both migraine and non-migraine headaches \[[@CR73]\]. The effect in migraine patients is variable. One out of two female migraine patients report no change of the headache pattern, 15% experience an improvement, while 28% report worsening \[[@CR74]\]. A negative effect occurs more often in migraine with aura \[[@CR72]\]. Headaches most frequently occur in the "pill-free" week \[[@CR53]\]. The neuronal nociceptive sensitivity is increased in this week and the probability of getting a headache is 20% higher \[[@CR74], [@CR75]\]. Higher age (\> 35 years) and a positive family history for migraine are risk factors \[[@CR76], [@CR77]\].

Possible contraceptive strategies to reduce headache include extended-cycle combined hormonal contraception, progesterone-only contraception or new generation hormones like estradiol valerate/dienogest \[[@CR17], [@CR62], [@CR78], [@CR79]\]. Eliminating the pill-free week is associated with improvement of headache, pelvic pain and quality of life \[[@CR55]\].

In progestin-only methods (oral pill, subdermal implant, depot-injection, levonorgestrel-releasing intrauterine system) headache is a common complaint at the beginning of therapy but classically improves after a few months. There is no known association between progestin-only methods and the worsening of migraine \[[@CR74]\]. On the contrary, frequency and intensity of migraine can significantly improve with this type of contraception. Ten percent of patients discontinue treatment due to side effects, particularly spotting \[[@CR80], [@CR81]\].

Migraine with aura is associated with a twofold risk of major cardiovascular events, like ischemic stroke. This risk is directly proportional to aura frequency \[[@CR55]\]. In the meta-analysis of Schürks et al. a relative stroke risk of 1.73 (95% CI 1.31-2.29) was found for any type of migraine. The relative risk of stroke in women suffering from migraine with aura is 2.08 (95% CI 1.3-3.31). The relative risk of cardiovascular deaths in women with migraine is 1.60 (95% CI 1.72-2.43) \[[@CR82]\]. Older combined hormonal therapies with high dosed estrogen (50--150 μg) are associated with a 4.4-fold risk of stroke in migraine patients, in particular in migraine with aura and should not be used anymore. The modern low-estrogen contraceptives (\< 25 μg) seem much safer \[[@CR55], [@CR56]\]. The 2017 consensus statement from the European Headache Federation and the European Society of Contraception and Reproductive Health recommends against the use of combined hormonal contraceptives in women with migraine with aura seeking hormonal contraception. They postulate a strong recommendation to prefer non-hormonal (condoms, copper-bearing intrauterine device, permanent methods) or progestogen-only alternatives. The same strategy is preferred in women with migraine without aura who have additional cardiovascular risk factors, like smoking, arterial hypertension, previous history of a trombo-embolic event. When there are no such risk factors, combined hormonal contraceptives are considered a possible contraceptive option with monitoring of migraine frequency and characteristics in women without aura. Other medical conditions like polycystic ovary syndrome or endometriosis can influence the risk/benefit profile and have an impact on the preferred type of contraception \[[@CR83]\].

#### Tension-type headache {#FPar5}

The impact of hormones on TTH is less frequently studied. Like migraine, TTH occurs more often in women than in men and some studies have suggested an increase during hormonal changes such as menses or pregnancy. Menstruation can be an aggravating factor in 40-60% of patients \[[@CR13]\]. There is no evidence that TTH is influenced by hormonal contraception \[[@CR77]\].

#### Cluster headache {#FPar6}

The hypothalamus is thought to be involved in CH pathophysiology based on its periodic time locked occurrence. Sex hormones appear to modulate hypothalamic activity and could be effective as a treatment for therapy refractory CH \[[@CR84]\]. Both male and female cluster patients show low testosterone levels and testosterone supplementation could have a positive effect on headache attacks \[[@CR2]\]. In the first studies from the early 1990s, testosteron supplementation did not prove effective, but more recent data show a good response in a subgroup of cluster patients \[[@CR84]\]. Clomifen is a selective estrogen modulator, primarily used for ovulatory stimulation in women. In men, it leads to an increase in luteinizing and follicle stimulating hormones (LH, FSH) and subsequently to higher testosterone levels. Furthermore, in animal model, it reduces prostaglandine production \[[@CR85]\]. In a case-series of 7 patients with chronic cluster headache and 8 patients with episodic cluster headache, Clomifen led to pain freedom after 15 days on average \[[@CR84]\].

Evidence of dysregulation of the hypothalamus-hypophysial axis in trigeminal autonomic cephalgias could be derived from a case with high nocturnal prolactin levels in a female patient suffering from short, unilateral, neuralgiform headache with conjunctival injection and tearing (SUNCT) \[[@CR86]\].

#### Other headache types {#FPar7}

Pituitary diseases are often associated with secondary headaches. Especially in female patients with prolactinoma, migraine-like headaches or worsening of a known migraine are reported. Mainly mechanic aspects such as compression of pain sensitive structures play a role in the development of headache, but probably increased hormonal secretion has an impact as well \[[@CR87]\]. Prolactin is involved in regulation of neuronal excitability and neurotransmission efficacy \[[@CR88]\]. Headache is commonly localized on the same side of the tumor and gets better after treatment with dopamine agonists \[[@CR89], [@CR90]\].

### Perimenopause {#Sec7}

Perimenopause is a period of decrease in reproductive capability in middle-aged women. During this period the growth and development of ovarian follicles stops and the pattern of estrogen and progesterone production changes. Signs of perimenopause include irregular menses and periodic amenorrhea starting several years before menopause, also called the menopausal transition. The average age of onset is 40 to 55 years and the average duration is 4 years, but in some women perimenopause can last from several months up to 10 years \[[@CR91]\].

The Stages of Reproductive Aging Workshop developed a classification for staging reproductive aging dividing a women's life into three stages based on the menstrual cycle: premenopausal (or reproductive), perimenopausal (or menopausal transition) and menopausal (or postmenopause) phase. There are two phases in the menopausal transition: the early phase, characterized by a variable cycle length (≥ 7 days), and a late amenorrhea phase. Postmenopause can also be divided into two stages. An early stage that lasts 5 to 8 years, characterized by amenorrhea length more than 1 year, low estrogen levels and high FSH level. The late stage is characterized by stable low levels of ovarian hormones \[[@CR92]\].

Perimenopause is characterized by fluctuations in both estrogen and progesterone levels. Due to these constant rapid changes in concentrations of ovarian hormones 60-70% of perimenopausal women experience symptoms such as headaches, flushing, mood swings, depression, decreased libido and sleep disturbance \[[@CR91]\]. The decrease of estrogen in the late luteal phase leads to low blood serum estrogen and progesterone levels and promotes prostaglandins release by the uterus influencing the menstrual cycle. This estrogen withdrawal becomes more frequent and longer and can have a secondary impact on headache patterns \[[@CR46], [@CR93]\].

#### Migraine {#FPar8}

Studies show that migraine prevalence in menopause is lower compared to the perimenopausal period. Menopausal transition seems to negatively impact migraine frequency \[[@CR94], [@CR95]\]. As perimenopause and menopause consist of several phases, each with a unique hormonal pattern, they all have a different effect on migraine. Another important factor is whether the menopause is naturally or artificially induced and whether HRT is used \[[@CR92]\].

Fluctuation in the estrogen level is a known migraine trigger. The hormonal alterations during perimenopause can provoke migraine attacks in 50% of women with menstrual migraine and menstrual related migraine. Rather stable levels of estrogen are replaced by a more fluctuating pattern with periods of rapid decline in estrogen concentration, the so called estrogen withdrawal \[[@CR95]--[@CR97]\]. The amount of estrogen withdrawal episodes is correlated to headache attack frequency in women with menstrual migraine in "early" perimenopause. Likewise women can experience an increase in menstruation frequency and in some cases an increase in vaginal bleeding duration and severity \[[@CR98]\]. This is related to an increase in uterine prostaglandins, which also influences central pain mechanisms and the trigeminovascular system provoking menstrual migraine attacks \[[@CR99], [@CR100]\]. Another potential mechanism that can increase menstrual migraine attack frequency is iron deficiency caused by menstrual bleeding \[[@CR101]\]. Depression, chronic pain syndrome and sleep disturbance can be other symptoms related to perimenopause, which in turn can lead to a secondary increase in migraine \[[@CR102]\].

Women suffering from the premenstrual syndrome were shown to experience more migraine attacks in late perimenopause. The attack frequency declines in the menopausal period. The premenstrual syndrome seems a predictor of migraine attack frequency increase for women entering menopause. These women are considered to have high sensitivity to hormonal fluctuations and liability to moderately severe climacteric symptoms, which in turn can have an impact on migraine \[[@CR92]\].

#### Migraine and hormonal replacement therapy (HRT) {#FPar9}

HRT is used to ease climax symptoms during menopausal transition. It seems to have a significant influence on migraine course. Studies confirm the correlation between the use of HRT, both oral and topical, and migraine \[[@CR103], [@CR104]\]. Oral high dosed estrogen can provoke new onset migraine with aura or worsening of pre-existent migraine with aura. Nappi et al. concluded that migraine deteriorated in women using oral estradiol plus medroxyprogesterone acetate. The course of the disease did not change with a transdermal patch \[[@CR105]\]. A few years later MacGregor et al. showed that transdermal patches with estrogen can be effective in decreasing migraine attack frequency in perimenopausal and postmenopausal women, supposedly more effectively than oral contraceptives \[[@CR106]\]. Gels and patches based on estradiol seem preferable over oral variants as constant blood hormones levels are maintained stable. They should be taken continuously without omission to prevent rapid changes in estrogen blood levels, a known trigger for migraine \[[@CR105], [@CR107]\]. These fluctuations in estrogen concentration have a more significant impact on migraine than progesterone levels. Nand et al. studied three groups of patients treated with different doses of progesterone combined with estrogen and revealed that changes in progesterone levels have no influence on migraine course \[[@CR92]\].

HRT containing low doses of natural estrogens are linked to an insignificant risk of thromboembolism, in contrast to the above mentioned combined oral contraception. Nevertheless HRT should be stopped immediately in case of a new onset migraine with aura, a clear increase in frequency or worsening of migraine with aura, transitory ischemic attack or other vascular pathology \[[@CR108]\].

#### Migraine and surgical menopause {#FPar10}

Natural menopause seems to reduce migraine frequency, in contrast to surgically induced menopause \[[@CR5]\]. Neri et al. studied a group of postmenopausal women \[[@CR109]\]. Improvement of migraine was seen in two thirds of cases compared to the premenopausal period. At the same time no reduction in days with TTH was observed. In women, who underwent ovariectomy the course of migraine worsened in the majority of women (67%). Thirtythree percent reported migraine improvement. In women with natural menopause 67% reported improvement in migraine course, in 24% of patients no change was observed and 9% reported worsening \[[@CR109]\]. There is still a debate on possible migraine worsening in women who undergo procedures such as hysterectomy, dilation and curettage or cesarean section. Arumugam and Parthasarathy found a positive correlation between these procedures and the prevalence of migraine in women \[[@CR110]\]. Oldenhave et al. compared a group of 986 hysterectomized women and 5636 women without hysterectomy with one or both ovaries preserved. The amount of days without migraine in the group without hysterectomy was less compared to the hysterectomy group. This data confirms the importance of presence or absence of the uterus on migraine frequency in menopausal women \[[@CR92]\].

#### Tension-type headache {#FPar11}

The most common risk factors for TTH are considered to be stress, fatigue and sleep disturbance. During perimenopause these symptoms can exacerbate and trigger TTH. But TTH also seems to have a correlation with reproductive hormone levels \[[@CR111]\]. In some women menstruation can trigger TTH and also pregnancy and menopause can influence the course of TTH \[[@CR93], [@CR111]\]. In retrospective evaluations 38% to 46% of women reported an increase of headache rate during menstruation \[[@CR112], [@CR113]\]. Arjona et al. even tried to identify "menstrual TTH" and "menstrual related TTH" based on ICHD-2 criteria for pure menstrual migraine and menstrually-related migraine. These terms were not included into the ICHD \[[@CR114]\]. Women in the perimenopause reported their headaches to have new characteristics and prevalence of TTH seems rather high \[[@CR115]\]. The prevalence of TTH in postmenopausal women is reported to be higher than in premenopausal women \[[@CR116]\].

#### Cluster headache {#FPar12}

According to the literature the course of CH in women is biphasic. The first peak of onset is seen around the age of 20 and the second at age 50 to 60. The majority of female cluster patients experience their first attack during menopause \[[@CR116], [@CR117]\]. The role of estrogen in CH and the reason for CH onset in these women remain unclear. Estrogen receptors are seen in the trigeminal ganglion and in sensory neurons which makes them susceptible to rapid changes in estrogen level \[[@CR118]\]. In menopause the reduced level of estrogen is assumed to provoke CH, while the higher estrogen level in the premenopausal phase can have a protective effect \[[@CR119]\]. However, based on the available literature, there is no clear evidence on the relationship between CH and hormonal changes in women \[[@CR120], [@CR121]\].

In 2006 van Vliet et al. published a large retrospective study in which data from more than 200 women with CH were analyzed using questionnaires. Among women with CH 9% reported more intense CH attacks during menstruation, while frequency didn't change. Eighty-six percent of women were using lifelong oral contraceptives in this trial. Initiation of oral contraceptives was associated with an increase of days with headache in 12% of participants. In 4% of the cases headache frequency was reduced. Out of 111 pregnant women with episodic CH 26 (23%) women reported "expected" CH attacks not to occur. After childbirth 8 of them experienced CH attacks in the first month. Nineteen patients (17%) had attacks during pregnancy and 11 of them did not report any changes in attack frequency or intensity \[[@CR120]\].

### Elderly {#Sec8}

In the elderly, headache is less frequent compared to younger patients. Headache disorders are mostly primary, but the relative frequency of secondary headache is higher in the elderly \[[@CR122]\]. In a random population sample, the prevalence of headache in women and men aged 55 to 74 years is approximately 66% and 53%, respectively, compared to 92% and 74%, respectively, in their younger counterparts between the ages of 21 to 34 years. The prevalence further declines in patients aged over 75 to 55% for women and 22% in men \[[@CR123]\]. In a population survey, the prevalence of frequent headache in elderly women was 20% and 10% in elderly men \[[@CR124]\]. Another survey showed a 3-month prevalence of headache among patients aged more than 66 years of 40.6% in men and 49.7% in women \[[@CR125]\]. In summary, all studies show that headache is more prevalent in women compared to men at all ages, even among the elderly. Hormonal factors take account for the sex-specific difference in headache prevalence. However, literature data about the relationship between headache and hormonal activity in elderly women are scarce. Only the relationship between migraine and estrogen has been extensively studied in older women, possibly because of the high prevalence of migraine and its sensitivity to hormonal fluctuations.

Up to 51.9% of elderly patients referred for specialist consultation report onset of headache after 65 years of age \[[@CR126]\]. Some primary headache disorders, and mostly hypnic headache, have the tendency to start after the age of 50, in contrast to most primary headache disorders, which usually start at a younger age. However, migraine still accounts for 0.5% of all new-onset headache disorders after the age of 65 \[[@CR127], [@CR128]\]. The low estrogen level in elderly women may explain why onset of migraine in this age group is uncommon. Migraine with onset at older age affects women and men equally, while in younger age groups women outnumber men \[[@CR129]\].

#### Migraine {#FPar13}

As mentioned above, the "estrogen withdrawal hypothesis" attributes migraine episodes to the fluctuation of estrogen levels throughout women's reproductive events. After menopause, women's serum levels of estradiol drop. A lower frequency and severity of migraine episodes is expected because of the stable low serum levels of estrogen. Migraine prevalence declines after menopause compared to the fertile period. However, the prevalence of migraine after the menopause is still 10 to 29% across studies \[[@CR5]\].

Interestingly, the decreased burden of migraine after the menopause is more evident in population-based studies when compared with those performed in headache clinics or menopause clinics \[[@CR94], [@CR109], [@CR115], [@CR130]--[@CR134]\]. This can be explained by a possible selection bias towards more severe forms of migraine in clinic-based studies as compared to population-based studies \[[@CR5]\]. Menopause has a different and variable effect on migraine with or without aura \[[@CR8]\]. In a population-based study, the burden of migraine without aura decreased after menopause while that of the variant with aura remained stable \[[@CR130]\]. In a headache clinic-based study migraine without aura remained unchanged or even worsened in the majority of patients possibly because of the above mentioned selection bias of clinic-based studies \[[@CR135]\]. Collectively, these data suggest that migraine without aura improves more frequently after menopause compared to migraine with aura. This can be a possible consequence of migraine without aura being more sensitive to female sex hormones \[[@CR5]\]. However, the available studies might have failed to show any change in the frequency of migraine with aura after the menopause because of low statistical power \[[@CR136]\]. When migraine with aura does not subside with age, characteristics may change, with increasing occurrence of aura without headache. These auras constitute a difficult differential diagnosis with transient ischemic attacks \[[@CR137], [@CR138]\]. An aura is generated by cortical spreading depression while migraine pain has been linked to the neurovascular system. Elderly subjects may exhibit an intact cortical spreading depression phenomenon, while the propensity to neurovascular inflammation declines \[[@CR139]\]. It is likely that those changes can be a consequence of the postmenopausal estrogen drop. However, to the best of our knowledge, this has not been proven yet.

Together with female sex hormones, male sex hormones might have an influence on the course of headache disorders among elderly women. Only one case-control study assessed the levels of androstenedione and testosterone in the serum of postmenopausal women with and without migraine and found no differences in the levels of these hormones when comparing women with and without migraine \[[@CR140]\].

In conclusion, the postmenopausal drop of estrogen might be beneficial for elderly women with migraine. However, the proportion of women experiencing migraine in menopause is still relevant.

#### Tension-type headache {#FPar14}

The effect of menopause on TTH is less clear than the corresponding effect on migraine. One population-based study addressing the topic found that the frequency of TTH decreased less than that of migraine after menopause. However, that same study pointed out that fluctuations of sex hormone levels during the life cycle might influence TTH as well as migraine \[[@CR131]\].

#### Hormonal therapy {#FPar15}

Hormonal manipulation in elderly women cannot be considered for migraine prevention at this time. HRT is contraindicated from 10 years after menopause or in women aged 60 years or older due to its potential cardiovascular side effects \[[@CR141]\]. No other hormonal therapy has been attempted in the prevention of migraine in elderly women. Clomiphene citrate has been used to treat chronic cluster headache and refractory primary SUNCT in single cases of elderly males \[[@CR142], [@CR143]\]. Clomiphene has a direct effect on hypothalamic estrogen receptors and estrogen modulates hypothalamic orexin expression. Hypothalamic estrogen receptors co-localize to orexin neurons. Therefore, clomiphene might upregulate orexin A levels, which in turn inhibits the trigeminal nucleus caudalis activity and secondarily suppresses the trigemino-autonomic reflex, preventing hypothalamic-driven headache \[[@CR142]\]. These results are promising in considering hormonal therapies as prevention for headache disorders in elderly women. However, there are no studies to date.

Males {#Sec9}
-----

### Migraine {#Sec10}

Migraine is notoriously known to be two to three times more prevalent in women than in men. Migraine is characterized by its fluctuating nature, where periods of remission are interspersed by relapse, with men more likely to have longer periods of remission compared to women. This female dominance of migraine suggests that factors increasing female vulnerability and/or protecting males deserve greater focus in migraine pathophysiology \[[@CR144]\]. Interestingly, a study has shown that male-to-female transsexuals who use antiandrogens to suppress male sex characteristics and estrogens to induce female sex characteristics have migraine rates similar to genetic females, further adding to the notion that gender-specific hormones play a role in migraine prevalence. The authors suggest that this similarity in migraine prevalence could include structural differences in the transsexual brain or that migraine headache is part of the female gender role \[[@CR145]\].

Animal models of migraine have attempted to investigate the gender specific difference in migraine prevalence. In an animal model of familial hemiplegic migraine type 1 (FHM1), it has been shown that orchiectomy increases susceptibility to cortical spreading depression, a response partially reversed with testosterone replacement \[[@CR146]\]. Also, female FHM1 mutant mice were more susceptible to cortical spreading depression than males \[[@CR146]--[@CR148]\].

Another explanation for increased prevalence of migraine in women could be attributed to inherent differences in pain perception and processing. The fundamental subjectivity of pain perception complicates quantification of pain, yet it is generally accepted that women and men experience pain differently due to both biological and psychosocial traits \[[@CR144]\]. Clinical studies are often not designed to decipher gender-specific difference \[[@CR149]\].

### Cluster headache {#Sec11}

In contrast to migraine, cluster headache has traditionally been considered a male disease \[[@CR150]\]. While the characteristic physical attributes of cluster headache patients could point to high testosterone levels, the exact opposite has been shown to be true \[[@CR151]\]. Low testosterone levels in patients with episodic and chronic cluster headaches were first noted in the 1970ies and later reproduced \[[@CR152]--[@CR154]\]. Another study found low testosterone levels in the episodic but not chronic cluster headache, a difference attributed by the authors to the disruption of REM sleep \[[@CR154]\].

The role of testosterone in cluster headache was further studied by Stillman et al. in their investigation of laboratory findings of 7 male and 2 female patients with treatment refractory cluster headache. Results of all 9 patients demonstrated low serum testosterone levels. After supplementation with either pure testosterone in the male patients or combination testosterone/estrogen therapy in the female patients, pain freedom was achieved for the first 24 h. Four male chronic cluster patients achieved headache remission. The authors concluded that abnormal testosterone levels in patients with episodic or chronic cluster headaches refractory to maximal medical management may be predictive of therapeutic response to testosterone replacement therapy \[[@CR2]\].

Discussion {#Sec12}
==========

Reviewing recent literature, it becomes evident that most experimental data on the causal relationship between sex hormones and primary headaches covers women suffering from migraine in the reproductive or perimenopausal phase of their life. Particularly the effect of estrogen has been studied and has been found to be of considerable value in the pathogenesis of migraine. The estrogen withdrawal hypothesis plays a central role here, but it is assumed that this is only part of the mechanism. Some therapeutic strategies have been developed based on this knowledge. Continuous combined contraceptive therapy regimes can be considered as a treatment for menstrual migraine. However, there is currently no evidence to support the superiority of hormonal therapy over non-hormonal pharmacological treatment strategies. When using hormonal therapies in migraine patients, whether it is as a contraceptive or as a treatment, potential cardiovascular risks should be considered when deciding which type of hormones to use.

For the other primary headaches and more so ever for headaches in male patients, the role of sex hormones is vague. Is there more to know? It seems plausible that trying to uncover the effects of sex hormones on the other primary headaches may offer new insights in pathophysiological mechanisms. The more we know on this matter, the more targeted possible new therapies can be.

Conclusion {#Sec13}
==========

All three primary headaches, migraine, TTH, and CH, occur in both genders, but with a sex-specific prevalence. Also, headache patterns display a temporal evolution that correlates to the hormonal shifts of a life cycle. Collectively, these findings suggest that both male and female sex hormones could play an important role in the pathophysiology of primary headaches. Reviewing the available literature on this matter, we can conclude that especially the role of estrogen in female migraine patients has been well-studied. Detailed studies especially in the elderly of both sexes, in CH, and TTH are warranted in order to clearly elucidate the role of sex hormones in not just migraine, but all primary headaches.

CGRP

:   Calcitonin gene-related peptide

CH

:   Cluster headache

FHM1

:   Familial hemiplegic migraine type 1

FSH

:   Follicle stimulating hormone

GABA

:   Gamma-aminobutyric acid

HRT

:   Hormonal replacement therapy

ICHD

:   International Classification of Headache Disorders

IHS

:   International Headache Society

LH

:   Luteinizing hormone

NMDA

:   N-methyl-D-aspartate

SUNCT

:   Short, unilateral, neuralgiform headache with conjunctival injection and tearing

TTH

:   Tension-type headache
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